Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1151120230310030206
Annals of Child Neurology
2023 Volume.31 No. 3 p.206 ~ p.214
Real-Life Efficacy and Tolerability of Lacosamide in Pediatric Patients Aged 4 Years or Older with Drug-Resistant Epile
Byun Shin-Yun

Kong Ju-Hyun
Lyu Soo-Young
Nam Sang-Ook
Kim Young-Mi
Yeon Gyu-Min
Lee Yun-Jin
Abstract
Purpose: The aim of this study was to evaluate the efficacy and safety of adjunctive lacosamide therapy in pediatric patients aged ¡Ã4 years with drug-resistant epilepsy (DRE).

Methods: Medical records of children aged 4 to 19 years treated with lacosamide as adjunctive therapy for DRE were retrospectively reviewed. The patients were divided into two groups according to their age at the start of lacosamide treatment: group A (aged 4?15 years) and group B (aged 16?19 years). Changes in seizure frequency from baseline, adverse events, and the retention rate were evaluated at each follow-up visit.

Results: Sixty-two patients (33 males and 29 females) with a mean age of 11.4 years (range, 4 to 19) were included. The mean duration of follow-up was 20.1¡¾12.9 months. The mean maintenance dose of lacosamide was 6.7¡¾4.8 mg/kg/day. Forty-two patients (67.7%) were responders (¡Ã50% reduction in seizures) with 19.4% (12/62) achieving freedom from seizures. The response rate did not differ significantly between groups A and B (67.6% vs. 68.0%, P=0.795) and was not affected by the concomitant use of sodium channel blockers. Significant independent factors associated with a good response to lacosamide treatment were a shorter duration of epilepsy (P=0.035) and fewer concomitant anti-seizure medications (P=0.002). Mild transient adverse events were observed in 20 patients (32.3%).

Conclusion: Lacosamide adjunctive therapy was efficacious and tolerated in children aged ¡Ã4 years with DRE. Early use of lacosamide may be helpful for a good response to drug-resistant seizures.
KEYWORD
Lacosamide, Anticonvulsants, Child, Pediatrics, Epilepsy
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø